Clinical trial
FazaClo Outcomes in the Control of Schizophrenia (FOCUS)
NCT00683891 is registered in ClinicalTrials.gov with Azur Pharma, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- FazaClo Outcomes in the Control of Schizophrenia (FOCUS)
- Lead sponsor
- Azur Pharma, Inc
- Phase
- Observational
- Overall status
- Completed
- Start date
- Not reported
- Completion date
- Not reported
- Enrollment
- Not reported
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.